XNYS · Medical Devices
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$324.29-0.44%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
47/100
Moderate
Score components
TickerWhale View
Stryker scores 47 out of 100 overall, which we rate moderate. Quality & growth is its strongest area and Risk its weakest.
What helps
- Quality & growth
What to watch
- Technical
- Valuation
- Risk
Quality & growth
30%61Positive
- Revenue growth 8.5%
- EPS growth 27.8%
Valuation
25%40Weak
- P/E 33.6
- EV/Sales 5.3
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
#100 by market cap in our coverage · ~56,000 employees · Listed 1979-05-02 · www.stryker.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#107 / 139sector rank by TickerWhale Score
TickerWhale Score 47 vs sector average 54.6 (-7.6)
Revenue growth (industry)Top 67%
Gross margin (industry)Top 61%
Return on equity (industry)Top 17%
P/E (industry)Pricier than 60%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
49/100Moderate vs universe
Ranks 49th of 100 covered names on our technical composite — the composite itself scores 56/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 1 sell · 4 neutral of 8 votes
TickerWhale rates SYK's technical setup middling — 49th percentile of the covered universe. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
9 / 9constructive
- vs 200-day+0.5%
- vs 50-day+11.0%
Momentum
Mixed
- RSI (14)60 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength18· weak trend
- MACD (12,26,9)buy(histogram 2.267)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 3 buy vs 1 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)33.6
- P/S (TTM)4.8
- P/B5.2
- EV/EBITDA—
- EV/Sales5.3
- PEG1.21
Profitability & returns
- Gross margin65.0%
- Net margin14.4%
- ROE15.9%
- Debt/Equity0.62
Growth
- Revenue growth (YoY)8.5%
- EPS growth (YoY)27.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $125.2B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $25.1B | $22.6B | $20.5B |
| Gross profit | $16.1B | $14.4B | $13.1B |
| Operating income | $4.9B | $3.7B | $3.9B |
| Net income | $3.2B | $3.0B | $3.2B |
| EPS (diluted) | $8.40 | $7.76 | $8.25 |
| Free cash flow | $4.3B | $3.5B | $3.1B |
| Cash | $4.0B | $3.7B | $3.0B |
| Total debt | $15.9B | $13.6B | $13.0B |
| Equity | $22.4B | $20.6B | $18.6B |
| Net debt | $11.8B | $9.9B | $10.0B |
| Debt / equity | 0.71 | 0.66 | 0.70 |
| Liabilities / assets | 0.53 | 0.52 | 0.53 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SYKCurrentStryker | 47 | 56 | 33.6 | — | 5.2 | 5.3 | $324.29 | -0.44% | +8.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.